Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHEDRA: Neoadjuvant Pyrotinib in HER2+ Breast Cancer
NCT03588091Phase 3Completed
- Sponsor
- Hengrui
- Start
- Jul 2018
- Primary completion
- Jan 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Pyrotinib + Trastuzumab + Docetaxel with Placebo + Trastuzumab + Docetaxel (2 arms). Primary endpoint: Pathological Complete Response (tpCR) by Independent Review Committee. Started Jul 2018; status: completed.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03588091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03588091.